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Abstract: Combined therapy emerges as an attractive strategy for cancer treatment. The 
aim of this study was to investigate the inhibitory effects of mitomycin C (MMC) combined 
with a novel antibody fragment (Fab) targeting latent membrane protein 1 (LMP1) on 
nasopharyngeal carcinoma (NPC) xenograft nude mice. The inhibitory rates of MMC   
(2 mg/kg), Fab (4 mg/kg), MMC (2 mg/kg) + Fab (4 mg/kg), and MMC (1 mg/kg) +  
Fab (4 mg/kg) were 20.1%, 7.3%, 42.5% and 40.5%, respectively. Flow cytometry analysis 
showed that the apoptotic rate of xenograft tumor cells in the MMC and Fab combination 
group was 28 ± 4.12%, significantly higher than the MMC (2 mg/kg) group (P < 0.01). 
Immunohistochemical staining showed that VEGF expression in NPC xenografts was 
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significantly inhibited in the combination group compared to the Fab (4 mg/kg) group  
(P < 0.05). In conclusion, both MMC and Fab could inhibit NPC xenograft tumor growth 
in vivo and combination therapy showed apparent synergistic anti-tumor effects, which 
may be due to the induction of tumor cell apoptosis and the downregulation of VEGF 
expression. These results suggest that the novel combined therapy utilizing traditional 
chemotherapeutics and antibody-targeted therapy could be a promising strategy for the 
treatment of NPC. 
Keywords:  mitomycin C; latent membrane protein 1; antibody targeted therapy; 
nasopharyngeal carcinoma; apoptosis; VEGF 
 
1. Introduction 
Nasopharyngeal carcinoma (NPC) is a kind of malignant tumor that originates from the epithelium 
of nasopharynx. During the progress of NPC, early cervical lymph node metastasis and distant 
metastasis may occur, representing a serious problem [1,2]. Current treatments of NPC are mainly 
radiotherapy and adjuvant chemotherapy, but the total five year survival rate is less than 40% and a 
series of side-effects are associated with radiotherapy and chemotherapy. Therefore, it is an urgent 
need to develop effective and safe therapeutics for NPC [3–5]. 
The infection with the Epstein-Barr virus (EBV) is one of the most important etiologic factors of 
NPC. EBV is a prototype gamma herpes virus that infects a large number of the population in the 
world and contributes to the pathogenesis of many EBV-associated cancers, including cervical 
carcinoma, gastrointestinal carcinoma and NPC [6,7]. Several latent genes are expressed during EBV 
infection, such as Epstein-Barr nuclear antigen 1 (EBNA1), latent membrane protein 1 (LMP1), 
LMP2A, and EBV-encoded RNAs (EBERs). LMP1 is a protein with unique characteristics and has 
been suggested as one of the major oncogenic factors by modulating several pathways involved in 
NPC, such as vascular endothelial growth factor (VEGF) [8]. Moreover, up to now LMP1 is the   
only latent protein implicated in the modulation of NPC cell differentiation, transformation and 
malignancy [9]. Consequently, LMP1 is a promising molecular target for NPC therapy. Although 
several therapeutic antibodies that target oncogenic products of EBV are currently approved for 
clinical treatment of NPC [10,11], targeted antibody therapy against LMP1 for NPC treatment has not 
been reported. In our previous study, we screened a humanized anti-LMP1 antibody Fab from a human 
naïve Fab phage library but its in vivo anti-tumor effect was not characterized [12]. 
Mitomycin C (MMC) is a classic chemotherapeutics which exhibits effective anti-tumor effects 
against a variety of solid tumors by inducing apoptosis and reducing drug resistance [13,14]. Notably, 
the inhibitory effects of MMC against NPC cells have been reported previously [15]. Combination 
therapy with various drugs is a common strategy in cancer treatment to obtain an additive or 
synergistic effect and to reduce the potential toxicity. So far, numerous MMC-containing combination 
remedies have been reported with encouraging clinical effects [16,17]. In this study, we designed a 
therapy remedy that combined the traditional chemotherapy drug MMC with a novel LMP1 antibody 
Fab, and evaluated the anti-cancer effects of this new combination therapy in NPC xenograft mice  Int. J. Mol. Sci. 2012, 13                 
 
 
2210
in vivo. Our results provided support for further preclinical studies to validate the effectiveness of a 
combined therapy using MMC and LMP1 Fab for NPC treatment. 
2. Results and Discussion 
2.1. MMC in Combination with Anti-LMP1 Fab Exhibits Synergistic Effect to Inhibit HNE2 Tumor 
Growth in Vivo 
We established HNE2 xenograft nude mice models that were treated with MMC alone, Fab alone or 
MMC plus Fab. No animal deaths were observed in the Fab or combination treated groups, but two 
mice in the MMC treated group died (on day 20 and day 25). As shown in Figure 1, on day 33 the 
tumor weight and size of PBS control group was 0.558 ± 0.062 g and 697.56 ± 77.48 mm
3, respectively. 
However, the tumor weight and size decreased to 0.446 ± 0.054 g and 557.88 ± 67.68 mm
3 in the MMC 
(2 mg/kg) treated group, and to 0.517 ± 0.047 g and 646.69 ± 59.18 mm
3 in the Fab   
(4 mg/kg) treated group, respectively. In addition, MMC (2 mg/kg) combined with Fab (4 mg/kg) 
resulted in a further reduction in both tumor weight (0.321 ± 0.054 g) and size (398.67 ± 64.87 mm
3). 
Interestingly, when we used decreased concentration of MMC (1 mg/kg) in combination with Fab  
(4 mg/kg) in xenograft nude mice, the tumor weight (0.332 ± 0.043 g) and size (419.44 ± 53.93 mm
3) 
were reduced remarkably compared with the control group and showed no difference in comparison to 
MMC (2 mg/kg) + Fab (4 mg/kg) group. The inhibition of tumor growth in each treatment group was 
summarized in Table 1. The results showed that both MMC and Fab showed an inhibitory effect on 
xenograft NPC tumor growth, but the combination therapy exhibited synergistic effect. 
Figure 1. Xenograft nasopharyngeal carcinoma (NPC) tumor growth in five groups. After 
the inoculation of 5 × 10
6 HNE2 cells/mL, 40 nude mice were randomly divided into   
5 groups and treated as indicated. The body weight (A) and tumor volume (B) were 
measured at different time points. After 33 days, all mice were sacrificed and tumors were 
removed and weighed (C). 
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Table 1. The inhibitory effects of mitomycin C (MMC) and Fab on NPC xenograft tumor 
growth  in vivo. Data were expressed as Mean ± SD (n = 6 for group I; n = 8 for   
group II–V). * P < 0.001 vs. group V; ** P < 0.05 vs. group III; *** P < 0.05 vs. group IV. 
Treatment groups 
Tumor volume (mm
3)  Tumor weight (g) 
Inhibition 
rate  Dosage (mg/kg) 
I: MMC (2 mg/kg)  557.88 ± 67.68 (*,**,***) 0.446 ± 0.054 (*,**)  20.1% 
II: Fab (4 mg/kg)  646.69 ± 59.18 (*,**,***) 0.517 ± 0.047 (*,**,***)  7.3% 
III: MMC (2 mg/kg) + Fab (4 mg/kg)  398.67 ± 64.87 (*)  0.321 ± 0.054 (*)  42.5% 
IV: MMC (1 mg/kg) + Fab (4 mg/kg)  419.44 ± 53.93 (*)  0.332 ± 0.043 (*)  40.5% 
V: PBS  697.56 ± 77.48  0.558 ± 0.062  - 
2.2. MMC in Combination with Anti-LMP1 Fab Exhibits Synergistic Effect to Induce the Apoptosis of 
HNE2 Cells in Vivo 
To investigate the potential mechanism by which MMC in combination with anti-LMP1 Fab 
exhibits synergistic effect to inhibit HNE2 tumor growth in vivo, we detected the apoptosis of xenograft 
tumor cells. Annexin V/PI assay showed that the percentage of apoptotic cells in control group was 
significantly less than that in MMC (2 mg/kg) treatment group (7.87% vs. 16.6%; P < 0.01). In combined 
therapy, the MMC (2 mg/kg) + Fab (4 mg/kg) treatment group showed a higher percentage of 
apoptotic cells than the control group (28% vs. 7.87%; P < 0.01) and MMC (2 mg/kg) treatment group 
(28% vs. 16.6%; P < 0.01). In addition, in combination therapy with decreased MMC concentration  
(1 mg/kg) and Fab (4 mg/kg), the percentage of apoptotic cells was still significantly higher than the 
control group (20.42% vs. 7.87%; P < 0.01) and MMC (2 mg/kg) group (20.42% vs. 16.6%; P < 0.05) 
(Figure 2). These results demonstrate that MMC synergized with anti-LMP1 Fab to induce the 
apoptosis of HNE2 cells in vivo. 
2.3. MMC in Combination with Anti-LMP1 Fab Exhibits Synergistic Effect to Inhibit VEGF 
Expression in HNE2 Cells 
Finally we detected VEGF expression in xenografts in nude mice by IHC. Compared with control 
group, VEGF expression in Fab (4 mg/kg) group, MMC (2 mg/kg) + Fab (4 mg/kg) group and MMC 
(1 mg/kg) + Fab (4 mg/kg) group was significantly inhibited (P < 0.01; Figure 3). In contrast, in MMC 
(2 mg/kg) group, VEGF expression was not decreased compared with control group (P > 0.05). The 
inhibitory effect on VEGF expression was most significant in the MMC (2 mg/kg) + Fab (4 mg/kg) 
group but there was no significant difference in VEGF expression between the two combination 
treatment groups (data not shown). Int. J. Mol. Sci. 2012, 13                 
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Figure 2. Flow cytometric analysis of the apoptosis of xenograft NPC tumor cells in   
five groups. After tumor tissues were excised and suspended, tumor cell suspensions were 
adjusted to a concentration of 1 × 10
6 cells/mL, and then resuspended in 250 μL of binding 
buffer, and stained with staining solution containing Annexin V/FITC and PI. The cells 
were analyzed using a FACScan flow cytometer. A: Representative flow histograms 
showing the apoptosis of tumor cells. I: MMC (2 mg/kg); II: Fab (4 mg/kg); III: MMC  
(2 mg/kg) + Fab (4 mg/kg); IV: MMC (1 mg/kg) + Fab (4 mg/kg); V: PBS. B: Comparison 
of apoptotic rates of xenograft tumor cells in different groups. * P < 0.01 vs. group V;  
** P < 0.01 vs. Group IV; *** P < 0.05 vs. group III and IV. 
 
Figure 3. Immunihistochemical staining of vascular endothelial growth factor (VEGF) 
expression in tumor samples of five groups. A: Representative immunohistochemical 
staining of VEGF in tumor cells in different groups. Positive staining was observed as 
brown. I: MMC (2 mg/kg), moderately to strongly positive staining; II: Fab (4 mg/kg), 
moderately positive staining; III: MMC (2 mg/kg) + Fab (4 mg/kg), weakly positive 
staining; IV: MMC (1 mg/kg) + Fab (4 mg/kg), weakly to moderately positive staining;  
B: Comparison of immunohistochemistry score (IHS) of VEGF in xenograft tumor cells in 
different groups. V: PBS, strongly positive staining. Magnification: 400×. * P < 0.01 vs. 
group V; ** P < 0.05 vs. group III. 
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2.4. Discussion 
Several cutting-edge treatment strategies have been developed for NPC, including molecular 
targeted therapy [18], EBV-based immunotherapy [19] and gene therapy [20]. However, no single 
treatment could achieve a satisfactory therapeutic outcome. Therefore, there is a trend to combine two 
or more drugs with different mechanisms of action for cancer therapy in clinical protocols. An 
elaborate strategy of combination therapy may enhance the therapeutic efficacy, decrease the potential 
toxicity, and minimize or restrain the development of drug resistance [21,22].  
In the present study, we observed that MMC and Fab was able to inhibit NPC xenograft tumor 
growth in a synergistic manner. Moreover, we found no significant difference in anti-tumor effects on 
tumor volume and weight between two combination therapy groups with different doses of MMC  
(2 mg/kg vs. 1 mg/kg). MMC is known to exhibit toxicity in vivo [23]. In this study, no animal death 
occurred in the Fab or combination treatment groups, while two mice in the MMC group died. 
Therefore, these results indicate that the lethal toxicity of MMC was reduced due to the combination 
with Fab. Similar observations were reported earlier on treating breast cancer xenografts with MMC 
and curcumin [24]. 
To evaluate the possible mechanism of synergistic anti-tumor effect of MMC and Fab, we 
performed flow cytometry analysis and found that MMC and Fab combination treatment induced 
significant higher apoptosis rate of NPC cells resuspected from xenografts compared to single 
treatment. In our previous in vitro study, we reported that MMC induced the apoptosis of NPC cells 
possibly by activating Caspase-3 [15]. Thus our in vivo data are consistent with those of in vitro 
experiments and suggest that MMC in combination with Fab exhibits synergistic effect to inhibit 
HNE2 tumor growth by inducing apoptosis. 
LMP1 is an integral membrane protein which contains three domains: an N-terminal cytoplasmic 
tail, six transmembrane-spanning loops and a C-terminal cytoplasmic region. The C-terminal region of 
LMP1 could trigger a variety of signaling pathways such as NF-κB, AP-1 and JAK/STAT to regulate 
the cell proliferation, immortalization, invasion and metastasis of NPC [7,9]. VEGF is one of the most 
significant downstream target genes of JAK3/STAT [25] and has been implicated in pathological 
angiogenesis associated with numerous kinds of tumors [26,27]. Interestingly, VEGF transcription and 
expression in NPC cell line are enhanced by LMP1 through JAK3/STAT3 pathway [28,29]. Therefore, 
we proposed that Fab against LMP1 could block the activation of JAK3/STAT3 pathway, thus 
inhibiting the expression of VEGF in NPC cells. While the elucidation of other mechanisms by which 
Fab inhibits NPC tumorigenesis is important and will be the focus of our further studies, the present 
data suggest that it is a feasible strategy to treat NPC by inhibiting LMP1 mediated upregulation of 
VEGF expression. In our previous study, we isolated Fab fragment against LMP1 from naïve Fab 
phage library Compared with a full-length antibody, this Fab fragment can be internalized by LMP1 
and are suitable for antibody-based immunotherapy [12]. Our results that Fab decreased VEGF 
expression in NPC xenograft tumors suggest that Fab neutralizes LMP1 and blocks LMP1 mediated 
downstream signaling. These may help explain the inhibitory effects of Fab alone or together with 
MMC on NPC growth in vivo. Further studies are necessary to elucidate the detailed mechanism by 
which Fab downregulates VEGF expression in NPC cells and examine whether JAK3/STAT pathway 
is involved. Int. J. Mol. Sci. 2012, 13                 
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3. Materials and Methods  
3.1. Reagents 
MMC was purchased from Hisun Pharmaceutical Co., Ltd (Zhejiang, China), dissolved in normal 
sodium as a 1 mM/L stock solution and stored at 4 °C in the dark. The anti-LMP1 antibody Fab was 
supplied by Key Laboratory of Ministry of Health, Nanjing Medical University (Jiangsu, China). 
VEGF antibody was obtained from Sigma (St. Louis, MO, USA). Second antibody was purchased 
from ZhongShan Goldbridge Co., Ltd (Shanghai, China). Annexin V-FITC apoptosis detection kit was 
purchased from Biouniquer Technology Co., Ltd (Shanghai, China). 
3.2. Cell Culture 
Human nasopharyngeal carcinoma cells HNE2-LMP1 (LMP1 positive) was purchased from 
Xiangya Central Laboratory (Hunan, China) and cultured in RPMI-1640 medium (Gibco, San Francisco, 
CA, USA) supplemented with 10% fetal calf serum (Gibco, San Francisco, CA, USA),   
penicillin (100 U/mL), and streptomycin (100 µg/mL). The cell culture was maintained at 37 °C with 
5% CO2 in a humidified atmosphere. 
3.3. In Vivo Tumor Xenograft Model 
Male 3-week-old BALB/C nude mice with a body weight of approximately 20 g were purchased 
from SLAC Laboratory Animal Co., Ltd (Shanghai, China), and maintained in standard vinyl cages 
with air filter tops in a filtered laminar air flow room at 25 °C on a 12 h light/dark cycle; water and 
food were autoclaved and provided. The experimental design for mice model was shown in Figure 4. 
For tumor establishment, 5 × 10
6 HNE2 cells/mL were washed twice with PBS and injected 
subcutaneously in a volume of 0.1 mL into the flank of mice. After inoculation, tumor-bearing mice 
were divided randomly into 5 treatment groups (8 mice per group) and treatment initiated when the 
xenograft solid tumors reached a volume of about 100 mm
3. Each mouse was injected intraperitoneally 
on day 1, 4, 7, 10 with different drugs as follows: group I: MMC alone (2 mg/kg); group II: Fab alone 
(4 mg/kg); group III: MMC (2 mg/kg) + Fab (4 mg/kg); group IV: MMC (1 mg/kg) + Fab (4 mg/kg); 
and group V: phosphate buffered solution (PBS) as negative control. The animal studies were 
conducted in accordance with public Health Service policy and approved by the Animal Care and Use 
Committee of Nanjing Medical University. After xenograft transplantation, mice bearing tumors were 
observed and tumor size was measured once every 3 days with vernier caliper. The tumor volume in 
each animal was estimated according to the formula: tumor volume (mm
3) = L × W
2/2 (where L was 
the length and W was the width) with the final measurement taken on day 33. At the same time, the 
body weight of each animal was measured once every 3 days. At the end of the experiments (on  
day 33), the animals were anaesthetized by CO2 and killed. Tumors from each animal were removed, 
measured and weighed individually. Inhibition rate of tumor growth was calculated by the following 
formula: Inhibition rate (%) = (tumor weight of control group − tumor weight of experimental 
group)/tumor weight of control group × 100%. The tumor tissues were also dissected and collected for 
further examination. Int. J. Mol. Sci. 2012, 13                 
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Figure 4. Experimental design of NPC xenograft nude mice model. The mice were s.c. 
implanted with HNE2-LMP1 cells for about 7 days until tumor volume reached around  
100 mm
3 and then randomly divided into five groups and treated as described in Materials 
and Methods. 
 
3.4. Annexin V/PI Assay for Apoptosis 
Tumor tissues from the mice in five groups were excised and suspended, respectively. Apoptosis of 
tumor cells was assessed by measuring membrane redistribution of phosphatidilserine using an 
Annexin V-FITC apoptosis detection kit (Biouniquer Technology, Shanghai, China) according to the 
manufacturer’s protocol. Tumor cell suspensions were prepared and washed with PBS, adjusted to a 
concentration of 1 × 10
6 cells/mL, then resuspended in 250 μL of binding buffer and stained with 
staining solution containing Annexin V/FITC and PI. The cells were analyzed using a FACScan flow 
cytometer (Becton-Dickinson Immunocytometry System), and the acquired data were analyzed. 
Additional exposure to propidium iodide (PI) made it possible to distinguish early apoptotic cells 
(Annexin-positive and PI-negative) from late apoptotic cells (Annexin- and PI- positive). All 
experiments were performed at least in triplicate. 
3.5. Immunohistochemistry  
The tumors from five groups were excised and then paraffin wax-embedded at Department of 
Pathology, Nanjing Medical University (Jiangsu, China). Sections (5 µm) were deparaffinized with 
xylene and then dehydrated in decreasing concentrations of alcohol. Endogenous peroxidase activity 
was blocked by hydrogen peroxidase (3%) in Tris-buffered saline (TBS) for 30 min. Then the sections 
were boiled for 10 min in citrate buffer for antigen retrieval. Nonspecific binding was blocked by 
incubation with 5% goat serum in TBS for 15 min. Next the sections were incubated with VEGF 
antibody in TBS containing 1% bovine serum albumin at 37 °C for 1 h, then washed with TBS and 
incubated with EnVision goat anti-mouse/horseradish peroxidase antibody (1:2000) for at 37 °C for  
1 h. The color was developed in diaminobenzidine solution and counterstained with Mayer’s 
hematoxylin. Four fields in each slide were randomly selected and counted, the percentage of positive Int. J. Mol. Sci. 2012, 13                 
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staining was determined by two clinical pathologists independently using immunohistochemistry score 
(IHS) [30]. When a conclusion differed, the final decision was made by consensus. IHS was 
determined by the evaluation of both staining density and intensity. The percentage of positive tumor 
cells was scored as follows: 1 (0–10% positive cells), 2 (11–50% positive cells), 3 (51–80% positive 
cells), 4 (81–100% positive cells); and the intensity of staining was scored as follows: 0 (negative),  
1 (weakly positive), 2 (moderately positive), and 3 (strongly positive). Multiplication of the intensity 
and the percentage scores gave rise to the ultimate immunoreactivity score: 0–1 (negative), 2–3 (weak), 
4–6 (moderate), and 8–12 (strong).  
3.6. Statistical Analysis 
All data were expressed as mean ± SD and analyzed with SPSS 18.0 statistic software (SPSS Inc, 
Chicago, IL, USA). Group differences in tumor weight and tumor growth inhibition rate were analyzed 
by a one-way ANOVA, and post hoc multiple comparison was performed with the LSD method. For 
all tests, the significance level for statistical analysis was set at P < 0.05. 
4. Conclusions  
In conclusion, in this study we combined chemotherapy and antibody targeted therapy to show that 
MMC and anti-LMP1 Fab combination exhibited synergistic effects to inhibit NPC tumor growth  
in vivo with high efficacy and much less toxicity associated with MMC. The anti-tumor effects appear 
to be mediated via the induction of apoptosis and the inhibition of VEGF expression. This novel 
combination therapy represents a promising strategy for the treatment of NPC. 
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